Jim Cramer on Medtronic (MDT): 'I Like This Medical Device Powerhouse'
We recently published a list of . In this article, we are going to take a look at where Medtronic plc (NYSE:MDT) stands against other stocks on Jim Cramer's radar.
On Friday's episode of Mad Money, Jim Cramer reflected on this week's market performance, with attention to upcoming earnings reports and broader market sentiment.
'Now we've been on a real rebound since post-Liberation Day meltdown back in the first week of April, with tech leading the way after really taking it on the chin.'
READ ALSO: Jim Cramer Recently Commented On These 12 Stocks and Jim Cramer Put These 8 Stocks Under a Microscope Recently
For this article, we compiled a list of 15 stocks that were discussed by Jim Cramer during the episodes of Mad Money aired on May 16. We listed the stocks in the order that Cramer mentioned them. We also provided hedge fund sentiment for each stock as of the fourth quarter of 2024, which was taken from Insider Monkey's database of over 1,000 hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points ().
A surgeon in a modern operating room holding advanced medical devices with a sense of purpose and accuracy.
Number of Hedge Fund Holders: 67
Noting Medtronic plc (NYSE:MDT) stock's inconsistency, Cramer advised investors to 'wait and see'.
'Also, Wednesday, we hear from Medtronic, and I like this medical device powerhouse, but the stock's been inconsistent even as the numbers tend to be pretty darn strong. That means it's hard to game. Another one, I gotta say, wait and see.'
Medtronic (NYSE:MDT) is a well-known global company in medical technology that specializes in the development and sale of a broad range of medical devices and treatments. For the fiscal year 2025, the company expects organic revenue growth between 4.75% and 5% for the year.
Additionally, Medtronic (NYSE:MDT) expects its diluted non-GAAP EPS to fall between $5.44 and $5.50, an expected increase of approximately 4.6% to 5.8% compared to the previous year.
Overall, MDT ranks 11th on our list of stocks on Jim Cramer's radar. While we acknowledge the potential of MDT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MDT and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Why Greif Stock Triumphed on Thursday
The company published its second earnings release of the current fiscal year. This pleased investors largely because of a sizable earnings beat. 10 stocks we like better than Greif › Veteran industrial company Greif (NYSE: GEF) was a standout on the stock exchange Thursday. Investors, captivated by a very convincing earnings beat in the company's freshly reported second quarter of fiscal 2025, pushed the industrial packing specialist's share price up by nearly 16%. In doing so, Greif not only crushed the S&P 500 index's performance on the day (it landed in the red by 0.5%), but also that of many blue chip stocks. Greif published those quarterly results just after market close on Wednesday, divulging that its net sales inched up by 1% on a year-over-year basis to hit nearly $1.39 billion. The dynamic was similar on the bottom line, with GAAP net income bumping 0.5% higher to $54.5 million, or $1.22 per share. Although the consensus analyst estimate for revenue was higher, at $1.42 billion, pundits tracking the stock underestimated profitability. Collectively, they were anticipating Greif would only earn $1.12 per share in net income. In its earnings release, Greif management indicated a steady-as-she-goes approach to its business. It quoted CEO Ole Rosgaard as saying that "The resilience of our results, supported by deliberate portfolio moves and operational discipline, demonstrates that Greif is well-positioned for success and value creation now and in the future." Greif cautiously proffered selected guidance for the entirety of this fiscal year, raising the low end of its projection for non-GAAP (adjusted) earnings before interest, taxes, depreciation, and amortization (EBITDA) to $725 million and its adjusted free cash flow to $280 million. Both estimates compare positively to the actual fiscal 2024 results of $694 million and just under $190 million, respectively. Greif isn't the most exciting company on the scene, but at times, it's the unexciting businesses that produce the most dependably pleasing results. This one does what it does well, and what's more it knows how to keep its investors happy with a relatively high-yield dividend. I think it' s a fine stock to own, even after the post-earnings pop. Before you buy stock in Greif, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Greif wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor's total average return is 789% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Greif Stock Triumphed on Thursday was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Here's How You Can Earn $100 In Passive Income By Investing In Air Products And Chemicals Stock
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Air Products and Chemicals Inc. (NYSE:APD) provides atmospheric gases, process and specialty gases, equipment, and related services globally. The 52-week range of Air Products and Chemicals stock price was $243.69 to $341.14. Air Products and Chemicals' dividend yield is 2.57%. It paid $7.16 per share in dividends during the last 12 months. Don't Miss: Invest Where It Hurts — And Help Millions Heal: Maximize saving for your retirement and cut down on taxes: . On May 1, the company announced its Q2 2025 earnings, posting revenues of $2.92 billion, missing the consensus estimate of $2.93 billion, as reported by Benzinga. Adjusted EPS fell 6% year-over-year to $2.69, missing the $2.83 consensus, as lower volumes and higher costs were partly offset by strong pricing. The company expects Q3 adjusted EPS of $2.90 to $3, compared to the consensus of $3.28. For full-year 2025, the adjusted EPS is expected to be between $11.85 and $12.15, lowered from the prior range of $12.70 to $13, and missing the consensus of $12.55. Check out this article by Benzinga for nine analysts' insights on Air Products and Chemicals. Trending: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." If you want to make $100 per month — $1,200 annually — from Air Products dividends, your investment value needs to be approximately $46,693, which is around 168 shares at $278.70 each. Understanding the dividend yield calculations: When making an estimate, you need two key variables — the desired annual income ($1,200) and the dividend yield (2.57% in this case). So, $1,200 / 0.0257 = $46,693 to generate an income of $100 per month. You can calculate the dividend yield by dividing the annual dividend payments by the current price of the stock. The dividend yield can change over time. This is the outcome of fluctuating stock prices and dividend payments on a rolling instance, assume a stock that pays $2 as an annual dividend is priced at $50. Its dividend yield would be $2/$50 = 4%. If the stock price rises to $60, the dividend yield drops to 3.33% ($2/$60). A drop in stock price to $40 will have an inverse effect and increase the dividend yield to 5% ($2/$40). In summary, income-focused investors may find Air Products stock an attractive option for making a steady income of $100 per month by owning 168 shares of stock. There may be more upside to come as investors benefit from the company's consistent dividend hikes. Air Products and Chemicals has raised its dividend consecutively for the last 43 years. Lower interest rates mean some investments won't yield what they did in months past, but you don't have to lose those gains. Certain private market real estate investments are giving retail investors the opportunity to capitalize on these high-yield opportunities. , which provides access to a pool of short-term loans backed by residential real estate. The best part? Unlike other private credit funds, Looking for fractional real estate investment opportunities? The features the latest offerings. Image: Shutterstock This article Here's How You Can Earn $100 In Passive Income By Investing In Air Products And Chemicals Stock originally appeared on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
an hour ago
- Business Insider
Bernstein Sticks to Its Buy Rating for Centene (CNC)
Bernstein analyst Lance Wilkes maintained a Buy rating on Centene (CNC – Research Report) today and set a price target of $86.00. The company's shares closed today at $55.16. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Wilkes covers the Healthcare sector, focusing on stocks such as UnitedHealth, Humana, and Elevance Health. According to TipRanks, Wilkes has an average return of -0.3% and a 42.86% success rate on recommended stocks. In addition to Bernstein, Centene also received a Buy from Wells Fargo's Stephen Baxter in a report issued yesterday. However, on June 2, Barclays downgraded Centene (NYSE: CNC) to a Hold.
